Abelacimab for atrial fibrillation when blood thinners aren’t suitable
Part of Heart & circulation clinical trials.
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign a consent form for this study.
- You have atrial fibrillation or atrial flutter confirmed on an ECG or heart monitor.
- You are 65–74 with a high stroke-risk score, or age 75+ with a high stroke-risk score.
- Your doctor has decided (before this study) that you’re not suitable for mouth blood thinners (because the bleeding risk is too high or you don’t want to take them).
- You have at least one bleeding-risk reason (like severe kidney problems, frequent antiplatelet use, prior bleeding in a serious area, frailty, or falls).
- Your doctor has also decided (before this study) that a left atrial appendage closure device isn’t suitable for you, or you won’t do the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called abelacimab for people with atrial fibrillation who cannot take standard blood thinners. The goal is to see if it safely reduces the risk of stroke or blood clots.
This trial tests a new medication to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard blood thinners. The drug works by blocking a different clotting factor, which may lower bleeding risks.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
This study tests a new approach for people with atrial fibrillation (a type of irregular heartbeat) who are also at high risk for stroke. It combines a procedure to fix the heart's electrical signals with closing off a small pouch in the heart to reduce stroke risk, potentially avoiding long-term blood thinners.
This study tests whether combining a heart procedure (catheter ablation) with a device to close the left atrial appendage (LAAO) is safer or better than blood thinners alone for frail patients 75 years or older with atrial fibrillation and high stroke risk. It aims to find a treatment that reduces stroke while lowering bleeding risks.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.